| Q41921001 | A 80-Year-Old Woman with B-Cell Prolymphocytic Leukemia |
| Q73441704 | Adjusted conditioning for allogeneic transplantation in a single center setting: mixed chimerism heralds relapse |
| Q35147065 | Alemtuzumab |
| Q36832113 | Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia |
| Q34785883 | Alemtuzumab in T-cell malignancies |
| Q35206362 | Alemtuzumab therapy in B-cell lymphoproliferative disorders |
| Q36768605 | Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use |
| Q34662884 | Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia |
| Q34589909 | Antibody therapy for chronic lymphocytic leukemia |
| Q34803868 | B-chronic lymphocytic leukemia: practical aspects |
| Q61651669 | CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells |
| Q33340504 | Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders |
| Q34785879 | Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia |
| Q77378845 | Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma |
| Q36490753 | Development of antibodies and chimeric molecules for cancer immunotherapy |
| Q57351083 | Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases |
| Q47722904 | Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed? |
| Q43947313 | Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population |
| Q34785898 | Future prospects for alemtuzumab (MabCampath). |
| Q74566806 | Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H |
| Q33873273 | Management of chronic lymphocytic leukaemia |
| Q35909297 | Monoclonal antibody therapy in lymphoid leukemias |
| Q81189032 | Monoclonal antibody therapy of cancer |
| Q54113253 | Phase I/II evaluation of pentostatin (2'-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia. |
| Q33371900 | Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia |
| Q38889962 | Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment |
| Q44198010 | Prolymphocytic leukaemia and Hodgkin's lymphoma |
| Q36115663 | Prolymphocytic leukemia |
| Q39409394 | Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation. |
| Q40750834 | Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients |
| Q45244361 | Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection |
| Q44637372 | Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H. |
| Q35164384 | Targeted therapies for the treatment of leukemia |
| Q37431603 | Targeted therapy for chronic lymphocytic leukemia |
| Q36057860 | Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies |
| Q73888073 | Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab |
| Q33359545 | Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection |